Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

USDTL launches two new tests for monitoring long-term alcohol exposure using fingernail, hair specimens

United States Drug Testing Laboratories launched two new tests for monitoring long-term alcohol exposure on Friday. Using fingernail and hair specimens, the new assay is the first and only test to report a donor's alcohol exposure for the past 90 days reliably.

10 Jan 2011

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.

7 Jan 2011

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

BG Medicine, Inc. announced today that it has entered into an agreement with Siemens Healthcare Diagnostics Inc., a division of Siemens Healthcare, one of the world's largest suppliers of clinical diagnostics to the healthcare industry, for the development and commercialization of a galectin-3 test for Siemens' automated immunoassay platforms for clinical laboratories.

7 Jan 2011

Biomarker study yields diagnostic blood test candidate for detection of Alzheimer's disease

OPKO Health, Inc. today announced the publication of a biomarker study yielding its diagnostic blood test candidate for the detection of Alzheimer's disease.

7 Jan 2011

Metabolon announces publication of 'Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy'

Metabolon, the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy", in the European Journal of Clinical Investigation.

6 Jan 2011

New technique to analyze and quantify changes in protein

A scientist from the Florida campus of The Scripps Research Institute has devised a new method of analyzing and quantifying changes in proteins that result from a common chemical process. The new findings could provide new insights into the effects of a highly destructive form of stress on proteins in various disease models, particularly cancer.

6 Jan 2011

Mutated TDP-43 can cause neurons to die: Study

Lou Gehrig's disease, or amyotrophic lateral sclerosis, and frontotemporal lobar degeneration are characterized by protein clumps in brain and spinal-cord cells that include an RNA-binding protein called TDP-43. This protein is the major building block of the lesions formed by these clumps.

6 Jan 2011

Scientists identify prognostic biomarker to treat patients with HCV

Scientists at Inserm and Institut Pasteur have performed biomarker discovery on patients being treated for chronic hepatitis C infection. Their work, published in The Journal of Clinical Investigation, demonstrates that the plasma levels of the protein IP-10 predict, prior to treatment initiation, the efficacy of treatment with pegylated-interferon and ribavirin.

6 Jan 2011

Cardiologists identify blood protein fragment that can predict heart attack

Cardiologists at the University of Connecticut Health Center have identified a protein fragment that when detected in the blood can be a predictor of heart attack.

6 Jan 2011

Odyssey Thera granted U.S. Patent for high-throughput screening of proteins

Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,855,167. The invention describes technologies and high-throughput methods for identifying bimolecular interactions in vivo based on protein-fragment complementation assays.

6 Jan 2011

Cell Biosciences introduces FluorChem M MultiFluor for detectig multicolor fluorescent Western blots

Cell Biosciences, a provider of innovative protein analysis tools to life science researchers, today announced the launch of the latest addition to their premier line of next-generation imaging products, the FluorChem M MultiFluor system.

5 Jan 2011

First whole genome sequence of Parsi breast cancer woman

Avesthagen Limited has yet again established its position as a leader in the successful application of next gen technologies as it announces the completion of the first Parsi breast cancer whole genome sequence of a 74-year-old Parsi woman with a heritable form of breast cancer. The incidence of breast cancer in most populations is strongly linked to a genetic basis but little is known about the variants at the present time.

4 Jan 2011

Clinical Data closes sale of genetic, pharmacogenomic testing and biomarker development business

Clinical Data, Inc. today announced that the Company has closed the sale of its genetic and pharmacogenomic testing and biomarker development business to Transgenomic, Inc. for $15.5 million. The sale completes Clinical Data's transformation into a pharmaceutical company with a deep product pipeline, including two promising late-stage compounds, the most advanced of which is vilazodone, a new treatment in development for Major Depressive Disorder.

30 Dec 2010

Researchers develop breath-analysis technology for rapid detection of biomarkers

Researchers have overcome a fundamental obstacle in developing breath-analysis technology to rapidly diagnose patients by detecting chemical compounds called "biomarkers" in a person's respiration in real time.

29 Dec 2010

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.

28 Dec 2010

Exiqon announces introduction of GLP compliant services for miRNA biomarker screening

Exiqon A/S, a leading provider of technologies for biomarker detection, today announced the introduction of GLP compliant services for miRNA biomarker screening and diagnostic assay development for clinical trials.

27 Dec 2010

Immunomedics announces additional claim for RS7 antibodies patent family

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that additional claims for the patent family, "RS7 antibodies," were issued as Patent No. 1,002,443 in Korea.

23 Dec 2010

AIDS patients with serum biomarkers are predisposed to immune reconstitution inflammatory syndrome

A study in this week's PLoS Medicine suggests that AIDS patients with cryptococcal meningitis who start HIV therapy are predisposed to immune reconstitution inflammatory syndrome - an exaggerated inflammatory immune response that kills up to one-third of affected people - if they have biomarkers in their blood showing evidence of a damaged immune system that is not capable of clearing the fungal infection.

22 Dec 2010

Exiqon completes discovery phase program for early detection of colorectal cancer in blood

Exiqon A/S today announced the completion of the discovery phase in its program for early detection of colorectal cancer in blood.

21 Dec 2010

Biomarker News and Research

Further Reading

QIAGEN to acquire minority stake in Alacris Theranostics

USDTL launches two new tests for monitoring long-term alcohol exposure using fingernail, hair specimens

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

Biomarker study yields diagnostic blood test candidate for detection of Alzheimer's disease

Metabolon announces publication of 'Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy'

New technique to analyze and quantify changes in protein

Mutated TDP-43 can cause neurons to die: Study

Scientists identify prognostic biomarker to treat patients with HCV

Cardiologists identify blood protein fragment that can predict heart attack

Odyssey Thera granted U.S. Patent for high-throughput screening of proteins

Cell Biosciences introduces FluorChem M MultiFluor for detectig multicolor fluorescent Western blots

First whole genome sequence of Parsi breast cancer woman

Clinical Data closes sale of genetic, pharmacogenomic testing and biomarker development business

Researchers develop breath-analysis technology for rapid detection of biomarkers

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Exiqon announces introduction of GLP compliant services for miRNA biomarker screening

Immunomedics announces additional claim for RS7 antibodies patent family

AIDS patients with serum biomarkers are predisposed to immune reconstitution inflammatory syndrome

Exiqon completes discovery phase program for early detection of colorectal cancer in blood

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News